Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
274 hedge funds and large institutions have $6.93B invested in Sage Therapeutics in 2018 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 95 increasing their positions, 90 reducing their positions, and 33 closing their positions.
30% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 33
2% more funds holding
Funds holding: 268 → 274 (+6)
6% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 90
2% more call options, than puts
Call options by funds: $63.1M | Put options by funds: $62.1M
0.6% more ownership
Funds ownership: 104.44% → 105.04% (+0.6%)
9% less capital invested
Capital invested by funds: $7.6B → $6.93B (-$673M)
50% less funds holding in top 10
Funds holding in top 10: 14 → 7 (-7)
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$58.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$36.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.1M |
| 2 |
Goldman Sachs
New York
|
-$30.7M |
| 3 |
Renaissance Technologies
New York
|
-$25.3M |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$16.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$15M |
SAGE Hedge Fund Activity: Q3 2018 in Review
274 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2018, worth a combined $6.93B — down 8.9% from $7.6B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new SAGE positions and 33 closed out — a net gain of 10 holders — while 95 added to existing stakes and 90 trimmed.
The largest buyer was Franklin Resources, adding an estimated $58.5M. The largest seller was Lord, Abbett & Co, cutting an estimated $37.1M.
- 274 institutional investors held Sage Therapeutics (SAGE) as of Q3 2018, up from 268 in Q2 2018.
- Funds reported $6.93B of Sage Therapeutics stock for Q3 2018, down 8.9% quarter-over-quarter.
- 43 funds opened new Sage Therapeutics positions in Q3 2018 and 33 closed out, a net change of +10 holders.
- The largest Sage Therapeutics buyer in Q3 2018 was Franklin Resources, an estimated $58.5M added.
- The largest Sage Therapeutics seller in Q3 2018 was Lord, Abbett & Co, an estimated $37.1M sold.
Based on aggregated 13F filings for Q3 2018.